SCHEMBL3736279

SCHEMBL3736279

Cc1c(Br)ccc2c1C(=O)C(=O)N2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CES1 P23141 8/20 0.47
▸ BCHE P06276 1/20 0.44
▸ TGM2 P21980 5/20 0.43
▸ MAPT P10636 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ DUSP3 P51452 1/20 0.38
▸ BLM P54132 1/20 0.38
▸ PTPN5 P54829 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ PTPN11 Q06124 1/20 0.38
▸ MCL1 Q07820 1/20 0.38
▸ CTDSP1 Q9GZU7 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.37
▸ ALDH2 P05091 1/20 0.37
▸ ALDH3A1 P30838 1/20 0.37
▸ HTT P42858 1/20 0.36
▸ ROS1 P08922 1/20 0.36
▸ CDK5 Q00535 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30838472 1.00 CES1 (0.47) CES1BCHETGM2MAPTMEN1
SCHEMBL3743988 0.80 CES1 (0.50) CES1BCHETGM2MAPTMEN1
SCHEMBL31728330 0.78 CES1 (0.48) CES1BCHETGM2MAPTMEN1
SCHEMBL29700199 0.77 CES1 (0.47) CES1TGM2MAPTMEN1POLB
SCHEMBL15353216 0.77 CES1 (0.47) CES1TGM2MAPTMEN1POLB
SCHEMBL2496190 0.77 CES1 (0.67) CES1BCHETGM2MAPTMEN1
SCHEMBL7827616 0.77 MAPT (0.52) CES1BCHETGM2MAPTMEN1
SCHEMBL6177499 0.77 CES1 (0.67) CES1BCHETGM2MAPTMEN1
SCHEMBL31103242 0.77 CES1 (0.67) CES1BCHETGM2MAPTMEN1
SCHEMBL7134014 0.76 RET (0.48) MAPTMEN1POLBBLMKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023002045-A1 FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF 3B PHARMACEUTICALS GMBH (DE) 2023-01-26 — — WO disclosed
EP-4122499-A1 FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF 3B Pharmaceuticals GmbH (DE) 2023-01-25 — — EP disclosed
US-7829567-B2 Imino-indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same KAOHSIUNG MEDICAL UNIVERSITY (TW) 2010-11-09 — — US disclosed
US-20090111987-A1 Imino-Indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same KAOHSIUNG MEDICAL UNIVERSITY (TW) 2009-04-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090111987-A1 Imino-Indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same IMPA1, IMPDH1, IPO5 CES1 2260/4885BCHE 3561/4885TGM2 4068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback